Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Nuvectis Pharma, Inc. Director's Dealing 2023

Jun 20, 2023

33912_dirs_2023-06-20_e2be7a2e-a662-468e-93e8-6af9dd03b408.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2023-06-16

Reporting Person: Oliviero James F III (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-06-16 Common Stock A 18000 Acquired 27828 Direct

Footnotes

F1: The 18,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Oliviero's continued service on the board on such dates.